FEG
REGN icon

Financial Enhancement Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Financial Enhancement Group’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-4
Closed -$3K – 276
2022
Q3 		$3K Hold
4
– – ﹤0.01% 226
2022
Q2 		$2K Hold
4
– – ﹤0.01% 248
2022
Q1 		$3K Buy
+4
New +$2.53K ﹤0.01% 235

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Financial Enhancement Group's REGN Position: Q4 2022 in Review

Financial Enhancement Group sold out of Regeneron Pharmaceuticals (REGN) in Q4 2022, closing a stake of 4 shares — an estimated $3K sold.

Financial Enhancement Group first reported a position in REGN in Q1 2022 and held it in 3 quarters. The position peaked at $3K in Q3 2022. 1,158 funds tracked by Wall St. Rank hold REGN as of Q4 2022.

  • Financial Enhancement Group reported no remaining Regeneron Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Financial Enhancement Group sold 4 Regeneron Pharmaceuticals shares in Q4 2022, an estimated $3K.
  • Financial Enhancement Group first reported a position in Regeneron Pharmaceuticals in Q1 2022 and held it in 3 quarters.
  • Financial Enhancement Group's Regeneron Pharmaceuticals position peaked at $3K in Q3 2022.
  • 1,158 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2022.

Based on Financial Enhancement Group's 13F filing for Q4 2022, filed 9 Feb 2023.